Laurberg G, Geiger J M, Hjorth N, Holm P, Hou-Jensen K, Jacobsen K U, Nielsen A O, Pichard J, Serup J, Sparre-Jorgensen A
Danish Study Group on Acitretin, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
J Am Acad Dermatol. 1991 Mar;24(3):434-7. doi: 10.1016/0190-9622(91)70067-c.
Sixty-five patients with lichen planus were included in a multicenter trial of acitretin. At the end of an 8-week placebo-controlled, double-blind phase, a significantly higher number of patients treated with 30 mg/day acitretin (64%) showed remission or marked improvement compared with placebo (13%). Furthermore, during the subsequent 8-week open phase, 83% of previously placebo-treated patients responded favorably to acitretin therapy. Typical retinoid adverse reactions were present in all patients on active drug. Laboratory studies did not show any clinically significant changes. This study shows that acitretin is an effective and acceptable therapy for severe cases of lichen planus.
65例扁平苔藓患者被纳入一项阿维A的多中心试验。在为期8周的安慰剂对照双盲阶段结束时，与安慰剂组（13%）相比，接受30mg/日阿维A治疗的患者中，有显著更多比例（64%）出现缓解或明显改善。此外，在随后8周的开放阶段，先前接受安慰剂治疗的患者中有83%对阿维A治疗反应良好。所有服用活性药物的患者均出现了典型的维甲酸类不良反应。实验室研究未显示任何具有临床意义的变化。这项研究表明，阿维A是治疗重度扁平苔藓的一种有效且可接受的疗法。
